84712-08-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological activity. It contributes to the development of new drugs with therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one is utilized as a building block in the preparation of agrochemicals. Its incorporation aids in the creation of effective compounds for agricultural applications, such as pesticides and herbicides.
Used in Organic Synthesis:
5-Bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one serves as a key component in the synthesis of other organic compounds. Its unique structure and reactivity make it a valuable precursor for the development of novel organic molecules with diverse applications in various industries.

Upstream product

• 41864-22-6 1,1'-Carbonyl-di-(1,2,4-triazole) 
• 337915-79-4 4-bromo-N²-methylbenzene-1,2-diamine 
• 6911-87-1 4-bromo-N-methylaniline 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 69038-76-2 2-N-methylamino-5-bromoaniline 
• 530-62-1 1,1'-carbonyldiimidazole 
• 161468-53-7 tert-butyl 6-bromo-2-oxo-2,3-dihydro-1H-benzo[d]-imidazole-1-carboxylate 
• 161468-45-7 tert‐butyl 2‐oxo‐2,3‐dihydro‐1H‐benzo[d]imidazole‐1‐carboxylate 
• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 75-44-5 phosgene 
• 59557-89-0 (4-bromo-2-methylphenyl)(methyl)amine 
• 53484-26-7 N-methyl-4-bromo-2-nitroaniline 
• 875-51-4 4-Bromo-2-nitroaniline 
• 339013-60-4 ethyl 6-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxylate 

Relevant academic research and scientific papers

Construction of Benzimidazolone Derivatives via Aryl Iodide Catalyzed Intramolecular Oxidative C-H Amination

The first aryl iodide catalyzed intramolecular C-H amination of phenylurea has been disclosed for high-efficiency synthesis of benzimidazolone derivatives in excellent yields (up to 97%) by an operationally simple one-step organocatalytic oxidative proces

Spiroconjugated Tetraaminospirenes as Donors in Color-Tunable Charge-Transfer Emitters with Donor-Acceptor Structure

Charge-transfer emitters are attractive due to their color tunability and potentially high photoluminescence quantum yields (PLQYs). We herein present tetraaminospirenes as donor moieties, which, in combination with a variety of acceptors, furnished 12 charge-transfer emitters with a range of emission colors and PLQYs of up to 99 %. The spatial separation of their frontier molecular orbitals was obtained through careful structural design, and two DA structures were confirmed by X-ray crystallography. A range of photophysical measurements supported by DFT calculations shed light on the optoelectronic properties of this new family of spiro-NN-donor-acceptor dyes.

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor overall kinase selectivity of putative RAF inhibitors. Herein, we describe 15 (LXH254, Aversa, R.; et al. Int. Patent WO2014151616A1, 2014), a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity. Our previous tool compound, 3 (RAF709; Nishiguchi, G. A.; et al. J. Med. Chem. 2017, 60, 4969), was potent, selective, efficacious, and well tolerated in preclinical models, but the high human intrinsic clearance precluded further development and prompted further investigation of close analogues. A structure-based approach led to a pyridine series with an alcohol side chain that could interact with the DFG loop and significantly improved cell potency. Further mitigation of human intrinsic clearance and time-dependent inhibition led to the discovery of 15. Due to its excellent properties, it was progressed through toxicology studies and is being tested in phase 1 clinical trials.

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).

SYK INHIBITORS

The present disclosure a Syk compound inhibitors, including state cancer and inflammation and various disease States thereof in the treatment of relates to the use of. In one aspect a particular embodiment, . given by formula I which is marked as a chemical structure of compound. In formula said, X 1, X 2, X 3, R 2, R 3, R 4, R 5, and Y has described herein is. The present disclosure of a formula I compounds or a pharmaceutically acceptable salt of pharmaceutical compositions including, mediated by Syk and to treat conditions a employing these compounds and compositions further provides a method. (by machine translation)

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid(benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

NOVEL HETEROCYCLIC COMPOUND

A drug having a high affinity for benzodiazepine ω3 receptors and showing curative and preventive effects for anxiety and depression, which comprises as the active ingredient, for example, a compound of the formula (1): wherein R1 an

Facile Synthesis of Benzimidazol-2-one Derivatives by Modified Lossen Rearrangement

A "formamide modification" has been applied to the Lossen rearrangement of several biologically important anthranilohydroxamic acids, some of them prepared for the first time.It has been found that a short heating at temperatures in the range 130-140 deg C converts these compounds into corresponding benzimidazol-2-ones with excellent yields.